Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
Speculative
4 exciting ASX small cap shares with explosive growth potential
⏸️ ASX Shares
3 excellent ASX healthcare shares to watch in the 2020s
Healthcare Shares
Can these 3 ASX healthcare shares outperform the index in 2020?
Speculative
3 exciting small cap ASX shares to watch in 2020
Share Market News
3 ASX healthcare shares to watch in 2020
Share Gainers
Why Amaysim, Evolution, Fluence, & Paradigm shares are pushing higher
Speculative
3 exciting small cap ASX shares to watch in 2020
⏸️ ASX Shares
Why these ASX healthcare shares could be market beaters in 2020
Share Market News
10 more top ASX shares to buy in 2020
Share Fallers
Why Challenger, Novita, Paradigm, and Xero are dropping lower
Speculative
10 exciting small cap ASX shares to watch in 2020
Share Fallers
Why FAR, Paradigm, Pro Medicus, & Redbubble shares are sinking lower
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
